COVID-19 Therapeutics

All COVID-19 treatments and therapeutics are authorized by the FDA. If you are at high risk of becoming seriously ill from COVID-19, talk to your healthcare provider to see if these treatments & therapeutics are right for you.

<table>
<thead>
<tr>
<th>Available Therapeutics</th>
<th>When to use them?</th>
<th>Who are they recommended for?</th>
<th>How/Where to get them?</th>
<th>Additional Guidance &amp; Resources</th>
</tr>
</thead>
</table>
| **Monoclonal Antibodies (mAbs)** | After testing positive for COVID-19 | **People 12 or older*** who:  
  ● Tested positive for COVID-19 and have had symptoms for 10 days or less  
  ● Are at high risk of becoming seriously ill  
  *Pediatric patients who are younger and at high risk should speak with their pediatrician as they may be able to receive a certain type of mAb product. | It is required that mAbs be administered in a setting where providers have direct access to medications to manage potentially severe adverse reactions. People should be referred for treatment by their healthcare providers and directed to available infusion locations. | ● ADHS - Monoclonal Antibodies  
● Combat COVID - How do I know if I’m at high risk?  
● Two mAb products, bamlanivimab/etesevimab and casirivimab/imdevimab, are not currently authorized for use due to markedly reduced susceptibility and are unlikely to be effective against the Omicron variant |
| **Long-Acting Antibodies (laAbs)** | Before being infected with COVID-19 | **People 12 or older:**  
  ● Who weigh at least 40 kg (88lbs)  
  ● Before being exposed to an individual with COVID-19  
  ● With moderate - severely compromised immune system  
  ● With history of severe adverse reactions to a COVID-19 vaccine and/or component(s) of those vaccines | Long acting Abs are an administered injection given by your healthcare provider to provide protection against COVID-19 for up to 6 months. | ● Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.  
● FAQs on Pre-exposure Prevention of COVID-19 |
| **Antivirals** | Within 5 days of symptoms starting and testing positive for COVID-19. | **People 12 or older*** who:  
  ● Weigh at least 40 kg (88lbs)  
  ● Tested positive for COVID-19  
  ● Have a high risk of severe COVID-19 disease progression  
  *Talk to your healthcare provider about what antiviral may be right for you as eligibility may vary. | Only available by prescription. Supply will only be available at select pharmacies across Arizona. Talk to your healthcare provider about getting treatment with oral antivirals. | ● Antiviral eligibility and requirements vary based on age and severity of illness.  
● Combat COVID - How do I know if I’m at high risk?  
● FAQs on treatment for COVID-19 |

*Last Update: 02/14/2022*
# COVID-19 Therapeutics

All COVID-19 treatments and therapeutics are authorized by the FDA for patients at high risk of developing severe illness from COVID-19. See below for additional guidance on treatments & therapeutics for patients.

<table>
<thead>
<tr>
<th>Available Therapeutics</th>
<th>When to use them?</th>
<th>Who are they recommended for?</th>
<th>How/Where to get them?</th>
<th>Additional Guidance &amp; Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monoclonal Antibodies (mAbs)</strong></td>
<td>To prevent SARS-CoV-2 disease progression in patients at high risk for developing severe COVID-19</td>
<td>People 12 or older who: ● Tested positive for COVID-19, and ● Are at high risk of becoming seriously ill from COVID-19</td>
<td>Treatment locations can be found on the ADHS Find Treatment website or contact the Arizona Poison Control Systems COVID-19 Hotline (844-542-8201) to find a site close to them that is administering monoclonal antibody therapies.</td>
<td>● ADHS - Monoclonal Antibodies (HCP) ● Side-by-Side Comparison ● NIH - Treatment Guidelines</td>
</tr>
<tr>
<td><strong>Long-Acting Antibodies (laAbs)</strong></td>
<td>Pre-exposure prophylaxis</td>
<td>People 12 or older: ● Weighing at least 40 kg (88lbs) ● Before being exposed to an individual with COVID-19 ● With moderate - severely compromised immune system ● With history of severe adverse reactions to a COVID-19 vaccine and/or component(s) of those vaccines</td>
<td>Treatment locations for Evusheld can be found on the ADHS Find Treatment website or contact the Arizona Poison Control Systems COVID-19 Hotline (844-542-8201) to find a site close to them that is administering monoclonal antibody therapies.</td>
<td>● Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. ● FAQs on Pre-exposure Prophylaxis of COVID-19 ● Evusheld Fact sheet for Healthcare Providers: Emergency Use Authorization</td>
</tr>
<tr>
<td><strong>Antivirals</strong></td>
<td>To prevent SARS-CoV-2 disease progression in patients at high risk for developing severe COVID-19</td>
<td>Oral Antivirals: People 12 or older* who: ● Weigh at least 40 kg (88lbs) ● Tested positive for COVID-19 ● Have a high risk of severe COVID-19 disease progression</td>
<td>Treatment locations can be found on the ADHS Find Treatment website or contact the Arizona Poison Control Systems COVID-19 Hotline (844-542-8201) to find a site close to them that is administering monoclonal antibody therapies.</td>
<td>● For additional information and resources for antiviral therapies ● Therapeutic Management of Hospitalized Adults with COVID-19 ● COVID-19 Outpatient Therapeutics Decision Guide</td>
</tr>
</tbody>
</table>

Last Update: 02/14/22